The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Broadening access for children & patients with inhibitor-complicated hemophilia
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
This marks one of the most closely watched oncology readouts at this year’s medical congress
Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
